Drugs / STA-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01475578 | Mar → Oct 2002 | vascular dementia | Sinphar Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01255046 Comparator | Dec 2015 → Dec 2018 | Alzheimer disease | Sinphar Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STA-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01255046 ↗ |
| Known as | Cistanche tubulosa | “STA-1 capsule (Cistanche tubulosa), 2 capsules/time, 3 times/day, orally” NCT01475578 ↗ |
| Route | Oral | “STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally” NCT01475578 ↗ |